162 related articles for article (PubMed ID: 24671680)
21. Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses.
Saito K; Shirasawa H; Isegawa N; Shiiba M; Uzawa K; Tanzawa H
Oral Oncol; 2009 Dec; 45(12):1021-7. PubMed ID: 19833547
[TBL] [Abstract][Full Text] [Related]
22. Construction and packaging of herpes simplex virus/adeno-associated virus (HSV/AAV) Hybrid amplicon vectors.
Saydam O; Glauser DL; Fraefel C
Cold Spring Harb Protoc; 2012 Mar; 2012(3):352-6. PubMed ID: 22383640
[TBL] [Abstract][Full Text] [Related]
23. Active immunotherapy: oncolytic virus therapy using HSV-1.
Todo T
Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
[TBL] [Abstract][Full Text] [Related]
24. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Martuza RL; Rabkin SD; Kurtz A
Mol Ther; 2006 Dec; 14(6):789-97. PubMed ID: 17045531
[TBL] [Abstract][Full Text] [Related]
26. "Armed" oncolytic herpes simplex viruses for brain tumor therapy.
Todo T
Cell Adh Migr; 2008; 2(3):208-13. PubMed ID: 19262110
[TBL] [Abstract][Full Text] [Related]
27. Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption.
Bommareddy PK; Peters C; Kaufman HL
Methods Enzymol; 2020; 635():167-184. PubMed ID: 32122544
[TBL] [Abstract][Full Text] [Related]
28. [The Advances of Oncolytic Herpes Simplex Virus in Cancer Therapy].
Hao M; Huang C; Xia N
Bing Du Xue Bao; 2016 Jul; 32(4):516-22. PubMed ID: 29996042
[TBL] [Abstract][Full Text] [Related]
29. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16.
Griffith C; Noonan S; Lou E; Shillitoe EJ
Cancer Gene Ther; 2007 Dec; 14(12):985-93. PubMed ID: 17853922
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
Lee CY; Rennie PS; Jia WW
Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
[TBL] [Abstract][Full Text] [Related]
31. Oncolytic HSV as a vector in cancer immunotherapy.
Li H; Zhang X
Methods Mol Biol; 2010; 651():279-90. PubMed ID: 20686972
[TBL] [Abstract][Full Text] [Related]
32. Improved antitumor effects elicited by an oncolytic HSV-1 expressing a novel B7H3nb/CD3 BsAb.
Zhang Z; Yang N; Lu H; Chen Y; Xu L; Wang Z; Lu Q; Zhong K; Zhu Z; Wang G; Li H; Zheng M; Zhang W; Yang H; Peng X; Zhou L; Tong A
Cancer Lett; 2024 Apr; 588():216760. PubMed ID: 38428724
[TBL] [Abstract][Full Text] [Related]
33. Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumors.
Fukuhara H; Takeshima Y; Todo T
Cancer Sci; 2021 Aug; 112(8):3293-3301. PubMed ID: 34036669
[TBL] [Abstract][Full Text] [Related]
34. Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors.
Hong B; Sahu U; Mullarkey MP; Kaur B
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062322
[TBL] [Abstract][Full Text] [Related]
35. Bovine herpesvirus type 1 as a novel oncolytic virus.
Rodrigues R; Cuddington B; Mossman K
Cancer Gene Ther; 2010 May; 17(5):344-55. PubMed ID: 19893594
[TBL] [Abstract][Full Text] [Related]
36. Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy.
Yao F; Murakami N; Bleiziffer O; Zhang P; Akhrameyeva NV; Xu X; Brans R
J Virol; 2010 Aug; 84(16):8163-71. PubMed ID: 20519407
[TBL] [Abstract][Full Text] [Related]
37. Replicative oncolytic herpes simplex viruses in combination cancer therapies.
Post DE; Fulci G; Chiocca EA; Van Meir EG
Curr Gene Ther; 2004 Mar; 4(1):41-51. PubMed ID: 15032613
[TBL] [Abstract][Full Text] [Related]
38. Genetic modification of oncolytic viruses to enhance antitumor immunity.
Davola ME; Vito A; Wei J; El-Sayes N; Workenhe S; Mossman KL
Methods Enzymol; 2020; 635():231-250. PubMed ID: 32122548
[TBL] [Abstract][Full Text] [Related]
39. Engineering HSV-1 vectors for gene therapy.
Goins WF; Huang S; Cohen JB; Glorioso JC
Methods Mol Biol; 2014; 1144():63-79. PubMed ID: 24671677
[TBL] [Abstract][Full Text] [Related]
40. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
Han ZQ; Assenberg M; Liu BL; Wang YB; Simpson G; Thomas S; Coffin RS
J Gene Med; 2007 Feb; 9(2):99-106. PubMed ID: 17256802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
